Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term breast cancer. Found 121 abstracts

no pagination
Blackwell KL, Zaman K, Qin S, Tkaczuk KH, Campone M, Hunt D, Bryce R, Goldstein LJ, Study G. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clin Breast Cancer. 2019 Apr;19(2):97-104 e4.
Pal T, Agnese D, Daly M, La Spada A, Litton J, Wick M, Klugman S, Esplin ED, Jarvik GP. Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2019 Dec 13;.
Reese JB, Smith KC, Handorf E, Sorice K, Bober SL, Bantug ET, Schwartz S, Porter LS. A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. Journal of psychosocial oncology. 2019 Mar;37(2):242-63.   PMCID: PMC6476670
West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer medicine. 2019 Aug 12;8(12):5609-18.   PMCID: PMC6745828
Zeinomar N, Phillips KA, Daly MB, Milne RL, Dite GS, MacInnis RJ, Liao Y, Kehm RD, Knight JA, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, Buys SS, John EM, Hopper JL, Terry MB. Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. International journal of cancer. 2019 Feb 06;145(2):370-9.   PMCID: PMC6525034
Martin JM, Goldstein LJ. Profile of abemaciclib and its potential in the treatment of breast cancer. Onco Targets Ther. 2018 Aug;11:5253-9.   PMCID: PMC6120573
O'Malley D, Dewan AA, Ohman-Strickland P, Gundersen DA, Miller SM, Hudson SV. Determinants of Patient Activation in a Community Sample of Breast and Prostate Cancer Survivors. Psychooncology. 2018 Jan 30;27(1):132-40.   PMCID: PMC5568503
Patel RS, Wen KY, Aggarwal R. Demographic Pattern and Hospitalization Outcomes of Depression among 2.1 Million Americans with Four Major Cancers in the United States. Medical sciences (Basel, Switzerland). 2018 Oct 24;6(4).   PMCID: PMC6313571
Churilla TM, Egleston B, Bleicher R, Dong Y, Meyer J, Anderson P. Disparities in the Local Management of Breast Cancer in the US according to Health Insurance Status. Breast J. 2017 Mar;23(2):169-76.
Dias MF, Blumenstein R, Russo J. Use of laser capture microdissection allows detection of loss of heterozygosity in chromosome 9p in breast cancer. Oncology Letters. 2017 May;13(5):3831-6.   PMCID: PMC5431386
Manne SL, Kashy D, Siegel SD, Heckman CJ. Group therapy processes and treatment outcomes in 2 couple-focused group interventions for breast cancer patients. Psychooncology. 2017 Dec;26(12):2175-85.   PMCID: PMC5548627
O'Malley D, Dewan AA, Ohman-Strickland P, Gundersen DA, Miller SM, Hudson SV. Determinants of Patient Activation in a Community Sample of Breast and Prostate Cancer Survivors. Psychooncology. 2017 Jan 30;.
Wen KY, Ma XS, Fang C, Song Y, Tan Y, Seals B, Ma GX. Psychosocial correlates of benefit finding in breast cancer survivors in China. Journal of health psychology. 2017 Nov;22(13):1731-42.
Wu D, Si M, Xue HY, Wong HL. Nanomedicine applications in the treatment of breast cancer: current state of the art. International journal of nanomedicine. 2017 Aug;12:5879-92.   PMCID: PMC5566389
Zhang FF, Haslam DE, Terry MB, Knight JA, Andrulis IL, Daly MB, Buys SS, John EM. Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry. Cancer. 2017 Jun;123(11):2070-9.   PMCID: PMC5444962
Bleicher RJ, Ruth K, Sigurdson ER, Daly JM, Boraas M, Anderson PR, Egleston BL. Breast conservation versus mastectomy for patients with T3 primary tumors (>5 cm): A review of 5685 medicare patients. Cancer. 2016 Jan;122(1):42-9.   PMCID: PMC4707052
Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015 Sep;4(9):e985930.   PMCID: PMC4570112
Holmberg C, Whitehouse K, Daly M, McCaskill-Stevens W. Gaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation - a qualitative study. Sociol Health Illn. 2015 Aug 03;37(8):1373-87.   PMCID: 4609249
Shaikh T, Tam TY, Li T, Hayes SB, Goldstein L, Bleicher R, Boraas M, Sigurdson E, Ryan PD, Anderson P. Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type. Breast J. 2015 Mar;21(2):121-6.
Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ. Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. Breast J. 2014 Jul;20(4):358-63.   PMCID: 4472437
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term breast cancer

breast cancer oncology prostate cancer Middle Aged Female Breast Neoplasms survivorship patient activation surgery Brca1 Brca2 Adult hybridization Novartis Genentech-and Genomic Health JMM has no conflicts of interest in this Lymph Node Excision insurance hereditary breast and ovarian cancer syndrome heterogeneity hematologic toxicity Chinese interventions Sentinel Lymph Node Biopsy Seer couple therapy molecular analysis narrative method Cdk4 breast cancer survivors human tumors Healthcare Disparities genetic heterogeneity sentinel node biopsy Tyrosine kinase inhibitor Combination drug therapy cancer neutropenic fever Segmental Mastectomy breast neoplasms breast radiotherapy multifocal Trastuzumab metabolism segmental mastectomy Tnbc work Age Factors epidemiology familial risk multicentric soy cdkn2 gene radiation therapy sexuality 80 and over Aged tumor infiltrating lymphocytes Medicaid psychotherapy pathology breast conservation survival rate mortality genetic testing SEER Program treatment outcome epithelial-cells ductal carcinoma loss of heterozygosity targeted delivery lung cancer Axilla inpatient psychiatry axillary lymph nodes colorectal cancer Registries Young Adult cancer survivors breast surgery Progesterone Receptors therapy Insurance Coverage biomarker in-situ ErbB-2 Receptor allelic loss survival sexual dysfunction Triple Negative Breast Neoplasms Her2 statistics & numerical data feasibility studies benign breast disease Lymph Nodes isoflavone Adolescent abemaciclib molecular subtype nanomedicine United States tumor microenvironment cyclin D1 drug resistance Health Insurance psychosocial couples' groups Estrogen Receptors Mdd clinical practice patterns Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm Risk Factors receptor status multigene panels laser microdissection metastasis working alliance Neratinib Medically Uninsured breast mortality 6 breast pathology randomised controlled trials (RCT) group processes chromosome 9p Lymphatic Metastasis breast-conserving surgery mastectomy Aged drug therapy women's health
Last updated on Friday, January 03, 2020